Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer - Abstract

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/R35, Cleveland, OH, 44195, USA.

The androgen receptor remains the key player in patients with castration-resistant prostate cancer (CRPC). Available agents capable of blocking early adrenal androgen production have limited activity and can lead to significant toxicities. Abiraterone acetate, a pregnenolone analog, is a small molecule that irreversibly inhibits CYP17, a rate-limiting enzyme in androgen biosynthesis. Several clinical trials have demonstrated the safety and efficacy of this compound in men with metastatic CRPC. Recently, a randomized phase 3 trial evaluating abiraterone acetate in docetaxel-refractory CRPC patients demonstrated a survival improvement over placebo-treated patients (14.8 vs 10.9 months; HR 0.646; P < 0.0001). A similar trial in the pre-chemotherapy setting has completed accrual and is undergoing analysis. Here we review the rationale and clinical development of abiraterone acetate in men with CRPC.

Written by:
Salem M, Garcia JA.   Are you the author?

Reference: Curr Oncol Rep. 2011 Jan 18. Epub ahead of print.
doi: 10.1007/s11912-011-0153-4

PubMed Abstract
PMID: 21243537

UroToday.com Prostate Cancer Section

email news signup